BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26044161)

  • 1. The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo.
    Eom KY; Cho BJ; Choi EJ; Kim JH; Chie EK; Wu HG; Kim IH; Paek SH; Kim JS; Kim IA
    Cancer Res Treat; 2016 Apr; 48(2):687-97. PubMed ID: 26044161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
    BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
    Lu XY; Cao K; Li QY; Yuan ZC; Lu PS
    J Int Med Res; 2012; 40(3):995-1004. PubMed ID: 22906272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
    Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
    Grossman R; Brastianos H; Blakeley JO; Mangraviti A; Lal B; Zadnik P; Hwang L; Wicks RT; Goodwin RC; Brem H; Tyler B
    J Neurooncol; 2014 Jan; 116(1):59-65. PubMed ID: 24185441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
    Tang JH; Ma ZX; Huang GH; Xu QF; Xiang Y; Li N; Sidlauskas K; Zhang EE; Lv SQ
    Exp Cell Res; 2016 May; 343(2):148-158. PubMed ID: 27090014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
    Kanzawa T; Bedwell J; Kondo Y; Kondo S; Germano IM
    J Neurosurg; 2003 Dec; 99(6):1047-52. PubMed ID: 14705733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
    D'Alessandro G; Grimaldi A; Chece G; Porzia A; Esposito V; Santoro A; Salvati M; Mainiero F; Ragozzino D; Di Angelantonio S; Wulff H; Catalano M; Limatola C
    Oncotarget; 2016 May; 7(21):30781-96. PubMed ID: 27096953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.
    Wang Y; Gao S; Wang W; Liang J
    Mol Med Rep; 2016 Dec; 14(6):5732-5738. PubMed ID: 27878252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
    Wang N; Zhang Q; Ning B; Luo L; Fang Y
    Biomed Pharmacother; 2017 Jun; 90():368-374. PubMed ID: 28380412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe.
    Pérès EA; Gérault AN; Valable S; Roussel S; Toutain J; Divoux D; Guillamo JS; Sanson M; Bernaudin M; Petit E
    Oncotarget; 2015 Feb; 6(4):2101-19. PubMed ID: 25544764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
    Fiveash JB; Gillespie GY; Oliver PG; Zhou T; Belenky ML; Buchsbaum DJ
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):507-16. PubMed ID: 18474311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide-induced modification of the CXC chemokine network in experimental gliomas.
    Bruyère C; Mijatovic T; Lonez C; Spiegl-Kreinecker S; Berger W; Kast RE; Ruysschaert JM; Kiss R; Lefranc F
    Int J Oncol; 2011 May; 38(5):1453-64. PubMed ID: 21399866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
    Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
    Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1.
    Wu H; Liu Q; Cai T; Chen YD; Liao F; Wang ZF
    Diagn Pathol; 2014 Sep; 9():173. PubMed ID: 25266957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
    Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
    Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells.
    Коbylinska LI; Klyuchivska OY; Grytsyna II; Finiuk N; Panchuk RR; Starykovych MO; Lehka L; Lesyk RB; Zіmenkovsky BS; Stoika RS
    Croat Med J; 2017 Apr; 58(2):150-159. PubMed ID: 28409498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.
    Kil WJ; Cerna D; Burgan WE; Beam K; Carter D; Steeg PS; Tofilon PJ; Camphausen K
    Clin Cancer Res; 2008 Feb; 14(3):931-8. PubMed ID: 18245557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
    Qi XC; Xie DJ; Yan QF; Wang YR; Zhu YX; Qian C; Yang SX
    Biochem Biophys Res Commun; 2013 Aug; 437(4):565-72. PubMed ID: 23850692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.